Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial
Janneke S. Hoogstad‐van Evert(Radboud University Nijmegen), Harry Dolstra(Radboud University Nijmegen), Anna L. de Goede(Radboud University Nijmegen), Nicolaas Schaap(Radboud University Nijmegen), Vanessa Rodríguez‐Fanjul(Radboud University Nijmegen), Joop H. Jansen(Radboud University Nijmegen), Hanny Fredrix(Radboud University Nijmegen), Bert A. van der Reijden(Radboud University Nijmegen), Nelleke Ottevanger(Radboud University Nijmegen), Lynn Bosmans(Radboud University Nijmegen), Ruud L.M. Bekkers(Radboud University Nijmegen), Petra L.M. Zusterzeel(Radboud University Nijmegen), Willemijn Hobo(Maastricht University Medical Centre), Paul K.J.D. de Jonge(Radboud University Nijmegen), Ellen Spijkers(Radboud University Nijmegen), Merlize Djojoatmo(Radboud University Nijmegen), Maud Wuts(Radboud University Nijmegen), Lisanne M. A. Janssen(Radboud University Nijmegen), Arnold van der Meer(Radboud University Nijmegen), Anniek B. van der Waart(Radboud University Nijmegen)
Cited by 6
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
|Journal of Clinical Oncology|2009|434